2005
DOI: 10.1016/j.urology.2004.08.005
|View full text |Cite
|
Sign up to set email alerts
|

Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
64
1

Year Published

2005
2005
2018
2018

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 104 publications
(73 citation statements)
references
References 20 publications
8
64
1
Order By: Relevance
“…Some of these SNPs are reportedly implicated in the risk of various types of cancers such as breast, prostate, bladder cancer and malignant melanoma (16)(17)(18)(19) and associations of the SNPs with plasma and urinary VEGF expression levels were demonstrated (20)(21)(22)(23). Genetic polymorphisms have also shown to affect the risk of cancer and the survival of cancer patients suggesting that polymorphisms as host genetic factors are partially involved in the progression and response to cancer treatments (24).…”
Section: Introductionmentioning
confidence: 99%
“…Some of these SNPs are reportedly implicated in the risk of various types of cancers such as breast, prostate, bladder cancer and malignant melanoma (16)(17)(18)(19) and associations of the SNPs with plasma and urinary VEGF expression levels were demonstrated (20)(21)(22)(23). Genetic polymorphisms have also shown to affect the risk of cancer and the survival of cancer patients suggesting that polymorphisms as host genetic factors are partially involved in the progression and response to cancer treatments (24).…”
Section: Introductionmentioning
confidence: 99%
“…Among these, the VEGF À634G/C, À1154G/A, and À2578C/A polymorphisms have been shown to be associated with an increased VEGF production (11 -13). Recently, VEGF polymorphisms were evaluated in melanoma (14) and bladder (15), lung (16), prostate (17), and breast cancer (18,19) patients. Various studies focused on the prognostic potential of VEGF polymorphisms (15,18,19).…”
mentioning
confidence: 99%
“…The TNF-α 308G/A polymorphism is a G/A polymorphism at nucleotide (nt) -308, and is associated with the development of several urogenital cancers, including prostate cancer (Zabaleta et al, 2008;Moore et al, 2009;Jones et al, 2013), cervical cancer (Singh, 2009;Zuo et al, 2011), bladder cancer (Jeong et al, 2004;Kim et al, 2005;Leibovici et al, 2005), and renal cell carcinoma (Jang et al, 2001). For example, Jeong et al (2004) studied 113 patients with bladder cancer and 109 healthy subjects and found that the genotype of the 308 nucleotide in the TNF-α promoter had a statistically significant effect on TNF-α production and was related to the bladder tumor grade.…”
Section: Discussionmentioning
confidence: 99%
“…There are 13 studies (Oh et al, 2000;McCarron et al, 2002;Wu, 2004;Jinchao, 2007;Danforth et al, 2008;Sáenz-López et al, 2008;Zabaleta et al, 2008;Kesarwani, 2009;Moore et al, 2009;Wang et al, 2009a;Zhang et al, 2010;Berhane et al, 2012;Jones et al, 2013) focusing on prostate cancer, 19 studies (Jang et al, 2001;Calhoun et al, 2002;Gostout et al, 2003;Stanczuk et al, 2003;Deshpande et al, 2005;Duarte et al, 2005;Govan, 2006;Kohaar et al, 2007;Singh, 2009;Wang et al, 2009b;Ivansson, 2010;Zu, 2010;Wang et al, 2011;Zuo et al, 2011;Badano et al, 2012;Barbisan et al, 2012;Hang and Xu, 2012;Wang et al, 2012;Sousa et al, 2014) on cervical cancer, 6 studies (Tsai et al, 2001;Jeong et al, 2004;Kim et al, 2005;Leibovici et al, 2005;Nonomura et al, 2006;Ahirwar et al, 2008) on bladder cancer, 1 study (Jang et al, 2001) on renal cell cancer, and 1 study (Wu, 2013) on urothelial carcinoma. Five articles (Stanczuk et al, 2003;…”
Section: Study Characteristicsmentioning
confidence: 99%